Fox Run Management’s Cytokinetics CYTK Stock Holding History

Fox Run Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-23,181	Closed	-$932K	–	943
2025 Q1	$932K	Buy	+23,181	New	+$1.07M	0.14%	228
2024 Q4	–	Sell	-3,870	Closed	-$204K	–	929
2024 Q3	$204K	Buy	+3,870	New	+$216K	0.05%	667
2022 Q4	–	Sell	-7,665	Closed	-$371K	–	677
2022 Q3	$371K	Buy	7,665 +1,845	+32%	+$88.8K	0.14%	278
2022 Q2	$229K	Buy	+5,820	New	+$234K	0.11%	385
2021 Q3	–	Sell	-16,978	Closed	-$336K	–	495
2021 Q2	$336K	Buy	+16,978	New	+$399K	0.31%	136
2018 Q3	–	Sell	-31,627	Closed	-$263K	–	623
2018 Q2	$263K	Buy	31,627 +20,405	+182%	+$170K	0.08%	485
2018 Q1	$81K	Sell	11,222 -10,953	-49%	-$93.9K	0.02%	685
2017 Q4	$181K	Buy	+22,175	New	+$252K	0.05%	587
2017 Q3	–	Sell	-36,000	Closed	-$436K	–	710
2017 Q2	$436K	Buy	+36,000	New	+$500K	0.15%	271
2016 Q1	–	Sell	-17,200	Closed	-$180K	–	443
2015 Q4	$180K	Buy	+17,200	New	+$169K	0.14%	319

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Fox Run Management's CYTK Position: Q2 2025 in Review

Fox Run Management sold out of Cytokinetics (CYTK) in Q2 2025, closing a stake of 23,181 shares — an estimated $932K sold.

Fox Run Management first reported a position in CYTK in Q4 2015 and held it in 10 quarters. The position peaked at $932K in Q1 2025. 311 funds tracked by Wall St. Rank hold CYTK as of Q2 2025.

Fox Run Management reported no remaining Cytokinetics position as of Q2 2025 after selling out during the quarter.
Fox Run Management sold 23,181 Cytokinetics shares in Q2 2025, an estimated $932K.
Fox Run Management first reported a position in Cytokinetics in Q4 2015 and held it in 10 quarters.
Fox Run Management's Cytokinetics position peaked at $932K in Q1 2025.
311 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2025.

Based on Fox Run Management's 13F filing for Q2 2025, filed 6 Aug 2025.